Pipeline.
Exaluren is being developed across two genetically defined kidney indications. Eloxx retains global rights to both kidney programs. ZKN-013 (rare skin diseases) is exclusively licensed to Almirall, S.A.
| Compound | Target | Indication | Status |
|---|---|---|---|
exaluren |
COL4A3 / COL4A4 / COL4A5 nonsense mutations | Nonsense mutation Alport syndrome (NMAS) |
EXACT Phase 2b
NCT07523581 → Program details → |
exaluren |
PKD1 / PKD2 nonsense mutations | Nonsense mutation ADPKD (NM-ADPKD) | Global Phase 2 — planning Program details → |
ZKN-013* |
COL7A1 / LAMA3 / COL17A1 nonsense mutations | Rare skin diseases (RDEB, JEB) — licensed to Almirall | Phase 1 (Almirall) |
* Eloxx has exclusively licensed ZKN-013 to Almirall, S.A., who is developing it for the treatment of rare skin diseases caused by nonsense mutations (RDEB and JEB). Almirall is responsible for all development and commercialization of ZKN-013.
All product candidates are investigational. Information current as of the most recent investor update.
Learn more about the EXACT Study
The EXACT Study is a Phase 2b clinical study of exaluren in people with nonsense mutation Alport syndrome. For background information, study design, and a link to the official ClinicalTrials.gov record (NCT07523581), visit the EXACT Study Information page.